These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 26806832

  • 21. Low turnover bone disease is the more common form of bone disease in CAPD patients.
    Rodriguez-Perez JC, Plaza C, Torres A, Vega N, Anabitarte A, Fernandez A, Lorenzo V, Hortal L, Palop L.
    Adv Perit Dial; 1992; 8():376-80. PubMed ID: 1361827
    [Abstract] [Full Text] [Related]

  • 22. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part IV of IV parts: The state of the bones in uremic hyperaparathyroidism--the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis.
    Parfitt AM.
    Metabolism; 1976 Oct; 25(10):1157-88. PubMed ID: 787723
    [Abstract] [Full Text] [Related]

  • 23. [A pathological analysis of 51 cases of renal osteodystrophy].
    Yu YF, Hu YX, Zhu P.
    Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):448-50. PubMed ID: 8275821
    [Abstract] [Full Text] [Related]

  • 24. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.
    Lehmann G, Stein G, Hüller M, Schemer R, Ramakrishnan K, Goodman WG.
    Kidney Int; 2005 Sep; 68(3):1206-14. PubMed ID: 16105052
    [Abstract] [Full Text] [Related]

  • 25. [Ultrasonography methods in the diagnosis of renal osteodystrophy].
    Tomić-Brzac H, Pavlović D.
    Acta Med Croatica; 2004 Sep; 58(1):43-9. PubMed ID: 15125393
    [Abstract] [Full Text] [Related]

  • 26. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
    Cantor T, Sci B.
    Nefrologia; 2003 Sep; 23 Suppl 2():69-72. PubMed ID: 12778858
    [Abstract] [Full Text] [Related]

  • 27. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7.
    González EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM, Sampath TK, Hruska KA.
    Kidney Int; 2002 Apr; 61(4):1322-31. PubMed ID: 11918739
    [Abstract] [Full Text] [Related]

  • 28. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?
    Ferreira JC, Ferrari GO, Neves KR, Cavallari RT, Dominguez WV, Dos Reis LM, Graciolli FG, Oliveira EC, Liu S, Sabbagh Y, Jorgetti V, Schiavi S, Moysés RM.
    PLoS One; 2013 Apr; 8(11):e79721. PubMed ID: 24236156
    [Abstract] [Full Text] [Related]

  • 29. Current concepts and management strategies in chronic kidney disease-mineral and bone disorder.
    Chauhan V, Kelepouris E, Chauhan N, Vaid M.
    South Med J; 2012 Sep; 105(9):479-85. PubMed ID: 22948328
    [Abstract] [Full Text] [Related]

  • 30. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y, Zhang H, Li Y, Li Q, Zuo L.
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Uremic toxin and bone metabolism.
    Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, Motojima M, Fukagawa M.
    J Bone Miner Metab; 2006 Jan; 24(2):172-5. PubMed ID: 16502128
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Osteoporosis and adynamic bone in chronic kidney disease.
    Cannata-Andía JB, Rodriguez García M, Gómez Alonso C.
    J Nephrol; 2013 Jan; 26(1):73-80. PubMed ID: 23023723
    [Abstract] [Full Text] [Related]

  • 35. The renal bone diseases in children treated with dialysis.
    Sanchez CP, Salusky IB.
    Adv Ren Replace Ther; 1996 Jan; 3(1):14-23. PubMed ID: 8620364
    [Abstract] [Full Text] [Related]

  • 36. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3 - 5.
    Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G.
    Clin Nephrol; 2008 Oct; 70(4):296-305. PubMed ID: 18826854
    [Abstract] [Full Text] [Related]

  • 37. Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.
    Kusano K, Saito H, Segawa H, Fukushima N, Miyamoto K.
    J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):99-105. PubMed ID: 19436134
    [Abstract] [Full Text] [Related]

  • 38. Effects of treatment of renal osteodystrophy on bone histology.
    Malluche HH, Mawad H, Monier-Faugere MC.
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
    [Abstract] [Full Text] [Related]

  • 39. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry.
    Coen G, Ballanti P, Balducci A, Grandi F, Manni M, Mantella D, Pierantozzi A, Ruggeri M, Sardella D, Sorbo G, Bonucci E.
    Am J Kidney Dis; 2006 Jul; 48(1):106-13. PubMed ID: 16797392
    [Abstract] [Full Text] [Related]

  • 40. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
    Kimmel PL, Langman CB, Bognar B, Faugere MC, Chawla LS, Watkins DW, Malluche HH.
    Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.